BioXcel Therapeutics Future Growth
Future criteria checks 3/6
BioXcel Therapeutics is forecast to grow earnings and revenue by 38.9% and 49.9% per annum respectively. EPS is expected to grow by 60% per annum. Return on equity is forecast to be 76.7% in 3 years.
Key information
27.2%
Earnings growth rate
54.0%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 48.8% |
Future return on equity | 76.7% |
Analyst coverage | Good |
Last updated | 26 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 21 | -65 | -51 | -37 | 4 |
12/31/2025 | 9 | -84 | -68 | -71 | 7 |
12/31/2024 | 3 | -97 | -84 | -91 | 6 |
12/31/2023 | 1 | -179 | -155 | -155 | N/A |
9/30/2023 | 1 | -212 | -167 | -167 | N/A |
6/30/2023 | 1 | -203 | -160 | -160 | N/A |
3/31/2023 | 1 | -187 | -155 | -155 | N/A |
12/31/2022 | 0 | -166 | -135 | -135 | N/A |
9/30/2022 | 0 | -137 | -117 | -117 | N/A |
6/30/2022 | N/A | -122 | -106 | -106 | N/A |
3/31/2022 | N/A | -112 | -95 | -95 | N/A |
12/31/2021 | N/A | -107 | -83 | -82 | N/A |
9/30/2021 | N/A | -102 | -83 | -82 | N/A |
6/30/2021 | N/A | -100 | -82 | -81 | N/A |
3/31/2021 | N/A | -94 | -74 | -74 | N/A |
12/31/2020 | N/A | -82 | -67 | -66 | N/A |
9/30/2020 | N/A | -69 | -54 | -54 | N/A |
6/30/2020 | N/A | -54 | -42 | -42 | N/A |
3/31/2020 | N/A | -41 | -34 | -34 | N/A |
12/31/2019 | N/A | -33 | -28 | -27 | N/A |
9/30/2019 | N/A | -32 | -25 | -24 | N/A |
6/30/2019 | N/A | -28 | -20 | -19 | N/A |
3/31/2019 | N/A | -22 | -19 | -18 | N/A |
12/31/2018 | N/A | -19 | -14 | -14 | N/A |
9/30/2018 | N/A | -15 | -10 | -10 | N/A |
6/30/2018 | N/A | -11 | -8 | -7 | N/A |
3/31/2018 | N/A | -8 | -3 | -3 | N/A |
12/31/2017 | N/A | -5 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BX2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BX2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BX2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BX2's revenue (49.9% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: BX2's revenue (49.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BX2's Return on Equity is forecast to be very high in 3 years time (76.7%).